Supplementary materials - Efficacy of Dupilumab in Patients From China With Type 2 Asthma and Elevated Blood Eosinophils

Name: Supplementary materials - Efficacy of Dupilumab in Patients From China With Type 2 Asthma and Elevated Blood Eosinophils
Creator: Changxing Ou
Published: 2026-08-05T12:41:26.563Z
Keywords: Asthma, Monoclonal Antibody, China, Eosinophil in Asthma

Ou, Changxing; Fu, Xiuhua; Fang, Haohui; Lin, Jie; Msihid, Jérôme; Huang, Yvonne; Fei, Yue; Kwah, Jason; Ledanois, Olivier; Zhong, Nanshan; Zhang, Qingling

doi:10.17632/75zhc9x29k.1

Supplementary materials - Efficacy of Dupilumab in Patients From China With Type 2 Asthma and Elevated Blood Eosinophils

Published: 5 August 2026| Version 1 | DOI: 10.17632/75zhc9x29k.1

Contributors:

,

, Haohui Fang,

,

, Yvonne Huang, Yue Fei,

,

Description

Online supplement for the Efficacy of Dupilumab in Patients From China With Type 2 Asthma and Elevated Blood Eosinophils letter, full text to be available online.

Files

Funders

Sanofi (United States)
Sanofi (France)
New Jersey, Bridgewater
Grant ID: NCT03782532
Regeneron (United States)
New York, Tarrytown
Grant ID: NCT03782532

Supplementary materials - Efficacy of Dupilumab in Patients From China With Type 2 Asthma and Elevated Blood Eosinophils

Description

Files

Categories

Funders

Licence